This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on September 10, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Assay Service for assessing ADME properties and in vivo PK properties with the selected vendor. ENAMINE US INC
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The National Institutes of Health, through the NIAAA Section on Medicinal Chemistry, is procuring chemical reagent assay development and laboratory testing services from Enamine US Inc. This firm fixed-price purchase order aims to assess the translational potential of novel molecular entities designed to treat metabolic and alcohol-associated diseases. The scope of work includes a comprehensive suite of ADME assays, specifically Caco-2, MDCK/MDR1, Hepatic Microsomal Stability, Plasma Protein Binding, and Plasma Stability, to evaluate oral absorption potential and transporter-related liabilities. Additionally, the contractor will perform an in vivo pharmacokinetic study using 25 male C57BL/6 mice to determine blood plasma and brain levels following IP or PO delivery. Key deliverables include detailed assay reports and a comprehensive electronic PK study report featuring raw data and calculations performed via Phoenix WinNonlin software. The period of performance is one year from the date of award, with payment issued in a single lump sum net 30 days after receipt of the deliverables. Inspection and acceptance of all services are the responsibility of the Project Officer or Project Officer Supervisor.
General Info
Place of Performance
Bethesda, MD, 20892, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The Section on Medicinal Chemistry (SMC) develops new molecular entities with implications in improving health and treatment for various metabolic and alcohol associated diseases. To assess the translational potential of novel molecular entities, which would allow us to make decisions to proceed the compounds for further development we utilize multiple derisking assays. These assays comprise of both cell-based (in vitro) testing and then eventually in mice to assess pharmacokinetic parameters to see if the drug is orally available.
Request to procure Chemical Reagent (Assay) Development & Laboratory Testing Service SMC to produce grouped ADME assays and perform a Pharmacokinetic study in C57BL6 mice. By including the Caco-2 Permeability Assay in our ADME evaluation it'll accurately predict the oral absorption potential of our compounds. This well-established in vitro model closely mimics the human intestinal epithelium, providing critical insights into a compound’s passive diffusion, active transport, and efflux processes, such as those mediated by P-glycoprotein (P-gp). The data generated from this assay are vital for informing structure-activity relationship (SAR) optimization, improving compound permeability, and reducing transporter-related liabilities that could hinder bioavailability
More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
